Long-term follow-up of people who received islet cell transplants for type 1 diabetes
Follows adults with type 1 diabetes who received working islet cell transplants for safety.
Key facts
- Who runs it
- Rodolfo Alejandro
- Where
- Miami, United StatesSee the site
- Trial code
- Registry title
- Long Term Follow up of Recipients of Functional Islet Allografts
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- Mar 2013
- Expected to end
- Dec 2029
- Type of study
- Observational
- Record updated
- 23 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who had an islet cell transplant in one of the listed earlier studies and whose transplanted islet cells still work. They still take medicines that calm the immune system.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- A working pancreatic islet graft that still needs immunosuppression, with no graft failure as defined in the earlier study.
- Earlier treatment
- Took part in one of the listed earlier islet transplant studies: 2000/0329; 2000/0196; 2004/0205; 2000/0024; 2006/0200; 2006/0508; 2006/0210.
Main reasons for not taking part
- Women with a positive pregnancy test or who are breast-feeding
- Women and men unwilling to use effective contraception during the study and for 4 months after
- Men who plan to have a child during the study or within 4 months after
- Any medical condition that, in the investigator's opinion, would make taking part unsafe
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Participation in any of the following parent studies: 2000/0329; 2000/0196; 2004/0205; 2000/0024; 2006/0200; 2006/0508; 2006/0210
- A functioning pancreatic islet graft (absence of graft failure as defined in parent study) requiring immunosuppression
- Willingness of participants to continue to use an approved method of contraception during and 4 months after study participation
- Ability to provide written informed consent
Who cannot take part
- Any medical condition that, in the opinion of the investigator, will interfere with safe participation in the trial
- For female subjects: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Diabetes Research InstituteMiami, United StatesContact: Rodolfo Alejandro, MDTaking people
About the trial
What the trial wants to find out
Since its inception, the Diabetes Research Institute (DRI) has made significant contributions to the field of diabetes, pioneering many of the techniques used in diabetes centers around the world. Through several clinical trials, DRI has demonstrated that diabetes can be successfully reversed as a result of islet cell transplant.
Read full original descriptionShow less
Over the years the following protocols in islet cell transplantation have been initiated: 2000/0329; 2000/0196; 2004/0205; 2000/024; 2006/0200; 2006/0508; 2006/0210.
All of the studies listed above will be source of study subjects for this study. Approximately 30 subjects are expected to be enrolled and followed in this trial.
After islet-cell transplantation in the parent studies, each subject receives maintenance immunosuppressive medications.
The purpose of this protocol is to collect additional follow-up for safety and efficacy from subjects with graft function after their completion in their parent study. It is expected that most subjects will retain measurable islet function and, in the islet-alone studies, continue to receive immunosuppressive medications at the time of completing their parent study.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long Term Follow up of Recipients of Functional Islet Allografts
- Plain-language title
- Long-term follow-up of people who received islet cell transplants for type 1 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT01999374, who can take part
- Publications
- Long-term Persistence of Allosensitization After Islet Allograft Failure.Transplantation, 2021
- Record updated
- 23 March 2026